The ongoing opioid epidemic in the United States has been fueled by prescription opioids. Increases in opioid-related deaths and complications mandate clinicians in all fields to scrutinize their prescribing patterns.
T he opioid epidemic in the United States is a national emergency. 1 From 2000 to 2014, nearly half a million persons died from drug overdoses, with 61% of overdose-related deaths in 2014 attributable to opioids. 2 In 2015, an estimated 1.9 million people in the United States met the criteria for opioid abuse or dependence. 3 The rise in opioid misuse, overdoses, deaths, and hospital admissions has increased in parallel with opioid sales, which quadrupled between 1999 and 2010. 4 Little is known about opioid prescribing patterns in dermatology. Evaluations of opioid prescriptions in other fields have encouraged changes in practice, [5] [6] [7] [8] [9] [10] [11] as even a short course of opioids can place patients at risk for addiction. 12 Current dermatology guidelines recommend oral opioids as second-line agents after a trial of nonsteroidal anti-inflammatory drugs and/or acetaminophen after surgical excisions and Mohs microsurgery (MMS). 13 Prior studies on opioid prescribing practices in dermatology suggest limited use of opioids after MMS but are derived from observational studies with limited cohorts of dermatologists and patients. 14, 15 In this study, we sought to broaden this evaluation by examining the use and potential complications associated with opioid prescriptions within the US Medicare population.
Methods

Data Collection
The Part D Prescriber Public Use File (PUF) is a public Centers for Medicare & Medicaid Services data set that contains information on prescription drug events incurred by Medicare beneficiaries with a Part D prescription drug plan. 16 The The top 1% of opioid prescribers and a random sample of the same size from the remaining dermatologists prescribing more than 10 opioid claims were identified using the Part D Opioid Prescriber Summary File for 2014, covering January 1 to December 31, 2014. Information on sex and geographic location were collected using the Part D Prescriber Look-Up Tool offered by the Centers for Medicare & Medicaid Services.
20
Graduation year from medical school and subspecialization were obtained from the prescriber's state medical board website. The type of each prescriber's practice was assessed by searching for descriptions of the practice on Google. Practices were designated as surgical if the prescriber practiced MMS or cosmetic surgery. Telephone calls were made to individual offices when clarification about the type of practice was needed.
Statistical Analysis
The number of dermatologists prescribing 0 opioid claims, 1 to 10 opioid claims, and greater than 10 opioid claims was calculated using the Part D Opioid Prescriber Summary File from 2014. All subsequent calculations for prescribing characteristics of dermatologists prescribing greater than 10 opioid claims and dermatologists in the top 1% of opioid prescribers were performed using the Part D Prescriber PUF for 2014. The mean number of days' supply per opioid claim was obtained by dividing the total days' supply for all opioid claims by the total opioid claim count. The mean number of opioid claims per beneficiary was determined by dividing the total opioid claim count by the total number of beneficiaries receiving opioids. The sex breakdown, geographic distribution, and type of practice among the top 1% of opioid prescribers and a random sample of remaining dermatologists prescribing more than 10 opioid claims were compared using a χ 2 test. The mean number of years since medical school graduation between these 2 groups was compared using a 2-sided t test. P < .05 was considered significant.
Mapping Geographic Variation
The opioid claim count was summed for each state and divided by the number of Medicare beneficiaries for that state 21 to yield the number of opioid claims per 1000 Medicare beneficiaries per state. The same calculation was repeated for states
Key Points
Question What is the nature and outcome of opioid prescriptions by dermatologists among Medicare patients?
Findings
In this cross-sectional study using 2014 Medicare Part D prescriber data, opioid prescriptions by dermatologists were few and concentrated among dermatologists in surgical practices.
Estimates project that this use could place more than 7000 Medicare beneficiaries at risk for addiction, more than 22 000 at risk for gastrointestinal tract or central nervous system adverse effects, and close to 1000 at risk for fractures.
Meaning Opioid prescribing among dermatologists is limited but associated with potential adverse effects for elderly patients; therefore, nonopioid alternatives should be emphasized.
grouped by geographic regions. State-based data were translated into a map with different colors corresponding to different amounts of opioid claims per 1000 Medicare beneficiaries.
Modeling of Risks
We performed a comprehensive literature search for observational studies and systematic reviews reporting the risks associated with opioid use in the setting of acute pain control, particularly in elderly patients (eTable 1 in the Supplement). Search terms included opioids, risks, elderly, acute, postoperative, and outpatient. References of articles were also manually searched for additional relevant studies. The rate of each adverse event was summarized as a range and then multiplied by the total number of beneficiaries receiving opioids in the 2014 Part D Prescriber PUF to obtain a projected number of affected Medicare beneficiaries. The predicted incidence of fracture for our population was calculated by taking the total days' supply derived from opioid claims in 2014 and dividing by 365 to obtain the number of person-years, which was then multiplied by the incidence of fracture reported per 1000 person-years in the literature. We next identified 115 dermatologists in the top 1% of dermatologists prescribing opioids. These dermatologists accounted for 42.2% of opioid claims and prescribed a total of 38 520 opioid claims to 32 205 beneficiaries. Each dermatologist prescribed a mean (SD) of 335 (234) opioid claims to 280 (148) beneficiaries, and each beneficiary received a mean of 1.2 opioid claims, with a supply of 4.2 days.
Among the top 1% of dermatologists prescribing opioids, 99 (86.1%) were male physicians, compared with 89 of 114 (78.1%) in a random sample of the same size from the remaining dermatologists prescribing more than 10 opioid claims (P = .11) ( Table 2) . A total of 108 dermatologists (93.9%) in the top 1% of prescribers worked in a surgical practice, vs 85 of 114 (74.6%) in the comparison group (P < .001). A total of 83 dermatologists (72.2%) in the top 1% had practices located in Southern states, with less of a geographic predominance among the random sample of remaining dermatologists (P = .003). The mean number of years since medical school graduation was 24 for both groups (P > .99).
Dermatologists in Southern states prescribed higher numbers of opioid claims per 1000 Medicare beneficiaries, compared with dermatologists in the rest of the United States (Figure) . Aggregated by region, dermatologists in the South prescribed 2.77 opioid claims per 1000 Medicare beneficiaries, compared with 1.60 in the West, 0.89 in the Midwest, and 0.83 in the Northeast (eTable 2 in the Supplement).
The frequencies of several risks associated with opioid use in the elderly, including addiction, gastrointestinal tract adverse effects (including constipation, nausea, and vomiting), central nervous system adverse effects (including dizziness, somnolence, and unsteadiness), and fracture, were identified from the literature ( Table 3) . 12, [22] [23] [24] [25] [26] [27] We estimate that 3877
to 7602 beneficiaries could continue to use opioids 1 year after their prescription and 1825 to 4029 may continue to use them 3 years after their prescription. A total of 9882 to 22 806 beneficiaries could experience gastrointestinal tract or central nervous system adverse effects and 588 to 999 could experience fractures. We also estimate a remainder of 493 204 unused opioid pills in the community.
Discussion
In this study, we investigate current opioid prescribing practices among dermatologists within the Medicare system and explore their implications for the Medicare population. These data suggest that opioid prescribing within dermatology is lim- Abbreviation: CNS, central nervous system.
Research Original Investigation Opioid Prescribing Patterns and Complications in the Dermatology Medicare Population
Dermatologists in southern states exhibit heavier use of opioids than those in other regions of the United States. Most dermatologists among the top 1% of opioid prescribers have practices located in southern states, exceeding the proportion practicing in the South among a random sample of dermatologists prescribing more than 10 opioid claims. Although we were not able to control for the volume of patients seen by these dermatologists, we concurrently found that dermatologists in southern states exhibit a higher opioid prescribing rate per 1000 Medicare beneficiaries, more than tripling the number prescribed in the Northeast. These observations are in line with previously reported increased prescribing rates among physicians in southern states, 28 pointing to regional influences on attitudes toward opioids that may benefit from region-specific interventions.
Although overall use of opioids may be low, short courses of opioids are associated with adverse effects, including addiction. The risk is likely potentiated in older adults, given agerelated changes in drug pharmacokinetics and the tendency toward polypharmacy among older adults. 29 Our calculations estimate that more than 7000 Medicare patients may be at risk for long-term opioid use from prescriptions they receive from dermatologists. Many more may be harmed from other adverse effects, including gastrointestinal tract adverse effects, central nervous system side effects, and fractures. The substantial number of potentially affected Medicare beneficiaries serves as a reminder to carefully weigh the risks of opioids when selecting agents for acute pain management. As suggested by current guidelines, nonsteroidal antiinflammatory drugs and acetaminophen should be used as first-line pain control agents, followed by opioids for additional control in certain high-risk patients. 13 After MMS, acetaminophen plus ibuprofen achieves lower pain scores with fewer adverse effects when compared with acetaminophen plus codeine. 30 Furthermore, 25% of patients undergoing MMS do not use any of their prescribed opioids and those who use their prescription take only 41% of their course, suggesting that patients may not require these drugs. 22 Based on these consumption habits, we calculated that a total of 493 204 pills could be left unused by Medicare patients receiving prescriptions from their dermatologist, creating a large opioid reservoir that poses a substantial risk for future misuse. Overall, the combination of patient and societal risks combined with the superior efficacy of nonopioid pain medications strongly suggests that dermatologists revisit habitual practices of prescribing opioids and consider the use of nonopioid pain medications alone in the management of acute pain.
Limitations
Our data must be interpreted in the context of the study design. The use of Medicare Part D data files limits our results to opioid prescribing practices among dermatologists participating in Medicare Part D and thus does not reflect prescribing practices applying to the general population of patients. Given the higher rates of skin cancer and the greater need for MMS among older adults, our findings may overestimate opioid prescribing by dermatologists to the general population. In addition, in our creation of the Figure, we used the number of Medicare beneficiaries enrolled in Parts A and B to calculate the number of opioid claims per 1000 Medicare beneficiaries per state. The use of data from different Medicare plans for this calculation may incorrectly estimate the rate of opioids per 1000 Medicare beneficiaries.
There are specific limitations associated with the use of Medicare Part D data files. The exclusion of data for claim counts or beneficiary counts with values below 10 in the 2014 Part D Prescriber PUFs prevents more accurate descriptions of opioid prescribing practices within Medicare. The data files also lack information on pill count per claim. We assume a mean of 5.4 leftover pills per claim based on the findings by Harris et al, 22 which limits the accuracy of our calculations for the number of leftover pills. The studies we used to model the risks of opioid use focused only on opioidnaive patients. However, we lack patient-level information to know the opioid status of our patients. Our extrapolations using data in opioid-naive patients may therefore misrepresent the number of patients affected by adverse events. Finally, although our analysis of the top 1% of opioid prescribers in dermatology suggests the use of prescription opioids in the setting of acute pain control, Medicare Part D data files do not provide information on the specific indications for opioid prescriptions to confirm our findings. Additional studies are needed to evaluate the full spectrum of indications for prescription opioids and to understand the decision making behind opioid prescribing practices within dermatology. Research in these areas will help to identify more specific recommendations to limit opioid prescribing by dermatologists.
Conclusions
Our study, in conjunction with the current literature, suggests that the prescription of opioids by dermatologists is limited and concentrated among dermatologists in surgical practices primarily in Southern states. Despite modest opioid prescribing practices, efforts must be made to reduce opioid prescriptions and minimize the risks associated with opioid use in the elderly Medicare population. When clinically appropriate, dermatologists should follow current guidelines recommending an initial approach using nonopioid agents alone for pain control in the postsurgical setting.
